URSODEOXYCHOLIC ACID

Read in conjunction with Disclaimer

Formulary: Restricted
Requires Neonatologist or relevant specialist review within 24 hours.

Presentation	**Oral Suspension:** 50 mg/mL
Drug Class	Gastrointestinal Medication
Indication	Treatment of neonatal cholestasis associated with parenteral nutrition, biliary atresia and cystic fibrosis
Special Considerations	Hypersensitivity to ursodeoxycholic acid Complete biliary obstruction
Monitoring	Liver function tests and serum bilirubin concentration Observe stool colour
Interactions	Antacids which contain aluminium bind to ursodeoxycholic acid and reduces its absorption.
Side Effects	**Common:** Nausea, vomiting, constipation, flatulence
	Infrequent: Transient increase in liver function test values
	Rare: Transient hypercholesterolaemia
Storage & Stability	**Oral Suspension:** Store below 25°C • Write date opened on bottle. • Discard suspension 4 months after opening.
Comments	• Consider fat soluble vitamin supplementation if required to prevent fat-soluable vitamin deficiency during cholestasis. • Contact pharmacy if commercial prepared oral suspension is not available due to supplier issues – compounding by pharmacy may be possible.

ORAL

Presentation	**Oral Suspension**: 50 mg/mL
Dosage	**Neonatal Cholestasis** 10 to 15 mg/kg every 12 hours • Dose adjustment • Renal and/or hepatic impairment: No adjustments provided by manufacturer's labelling.
Administration	• Shake well before use • Draw prescribed dose into oral/enteral syringe • Can be given Oral/OGT/NGT • May be given anytime in relation to feeds

Related Policies, Procedures, and Guidelines

HDWA Mandatory Policies: N/A

Clinical Practice Guidelines: N/A

WNHS Pharmaceutical and Medicines Management Guidelines: N/A

References

Australian Medicines Handbook. Ursodeoxycholic Acid. In: Australian Medicines Handbook [Internet]. Adelaide (South Australia): Australian Medicines Handbook; 2024 [cited 2024 Feb 9]. Available from: https://amhonline.amh.net.au/

Truven Health Analytics. Ursodiol. In: NeoFax [Internet]. Greenwood Village (CO): Truven Health Analytics; 2024 [cited 2024 Feb 9]. Available from: https://neofax.micromedexsolutions.com/

Takemoto CK, Hodding JH, Kraus DM. Pediatric & neonatal dosage handbook with international trade names index : a universal resource for clinicians treating pediatric and neonatal patients. 27th ed. Hudson (Ohio): Lexicomp; 2020. p2367-2368.

Document history

Keywords	Ursodeoxycholic Acid, Ursodiol, Ursofalk, Cholestasis				
Document Owner:	Chief Pharmacist				
Author/ Reviewer	KEMH & PCH Pharmacy/Neonatology Directorate				
Version Info:	4.0 – full review, new template				
Date First Issued:	31/01/2001	Last Reviewed:	09/02/2024	Review Date:	09/02/2029
Endorsed by:	Neonatal Directorate Management Group			Date:	27/02/2024
NSQHS Standards Applicable:	☒ Std 1: Clinical Governance		☒ Std 4: Medication Safety		
Printed or personally saved electronic copies of this document are considered uncontrolled. Access the current version from WNHS HealthPoint.					

This document can be made available in alternative formats on request for a person with a disability.